• NEBANNER

Renewable Design for Oil Water Separation Process - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Renewable Design for Oil Water Separation Process - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Attaining consumer satisfaction is our company's purpose without end. We will make wonderful endeavours to produce new and top-quality merchandise, satisfy your exclusive requirements and supply you with pre-sale, on-sale and after-sale services for Water Filter For Iron Removal, Filtration In Water Treatment, Water Treatment, Our merchandise are widely recognized and trusted by users and can meet up with continuously changing economic and social needs.
Renewable Design for Oil Water Separation Process - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN Detail:

Used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

It is used to prevent or reduce the formation of thrombosis, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

The recommended dose is oral rivaroxaban 10mg, once a day. Rivaroxaban 10mg can be taken with food or alone. Rivaroxaban 15mg or 20mg tablets should be taken with food.

standard: usp40
Assay: 99-102%

Exterior: White powder
Package : 25kg/drum

Take 4-(4-aminophenyl) morpholin-3-one (SM-1), (S)-N-glycidyl phthalimide (SM-2), 5-chlorothiophene-2- Formyl chloride (SM-3) is the starting material. After condensation, cyclization, aminolysis and acylation, the crude rivaroxaban is obtained, and the finished rivaroxaban is refined.
Preparation: This product is a red film-coated tablet.

Accessories:
Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate
Coating: polyethylene glycol, hypromellose, titanium dioxide, iron oxide red

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. Through highly selective and competitive inhibition of free and bound factor Xa and prothrombin activity, prolong the activated partial thromboplastin time plate (PT) and prothrombin time (aPTT) in a dose-dependent manner, which can interrupt the coagulation waterfall The endogenous and exogenous pathways inhibit the production of thrombin and thrombosis. Rivaroxaban does not inhibit thrombin (activating factor Ⅱ), nor has it proven to have an effect on platelets
The essential difference between rivaroxaban and fondaparinux/heparin is that it does not require the participation of antithrombin III and can directly antagonize free and bound factor Xa; while heparin requires antithrombin III to function, and It has no effect on factor Xa in the prothrombin complex.


Product detail pictures:

Renewable Design for Oil Water Separation Process - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN detail pictures


Related Product Guide:

To be a result of ours specialty and service consciousness, our enterprise has won an excellent status between buyers all around the globe for Renewable Design for Oil Water Separation Process - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN , The product will supply to all over the world, such as: Canada, Stuttgart, Spain, Wide selection and fast delivery to suit your needs! Our philosophy: Good quality, great service, keep improving. We've been looking forward that more and more oversea friends join in our family for further development near the future!
  • We always believe that the details decides the company's product quality, in this respect, the company conform our requirements and the goods are meet our expectations.
    5 Stars By Margaret from Bogota - 2018.12.25 12:43
    Good quality and fast delivery, it's very nice. Some products have a little bit problem, but the supplier replaced timely, overall, we are satisfied.
    5 Stars By Irene from Japan - 2018.06.30 17:29
    Write your message here and send it to us